スポンサーリンク
Department Of Pathology Okayama University Medical School And Graduate School Of Medicine Dentistry | 論文
- Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Clonal Analysis of Bilateral, Recurrent, or Systemically Multifocal Ocular Adnexal Lymphoma
- Different Kinetics of WT1 and PML-RARα Gene Expression Levels during Remission Induction Therapy with All-trans Retinoic Acid Alone in Acute Promyelocytic Leukemia
- Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
- Acquired hemophilia A with sigmoid colon cancer : successful treatment with rituximab followed by sigmoidectomy
- A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma : β2-microglobulin associated with time to progression
- Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia
- Increased Expression of Insulin-Like Growth Factor I is Associated with Ara-C Resistance in Leukemia
- Imatinib Mesylate in Conjunction with Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Philadelphia Chromosome Positive Leukemias : Report of 4 Cases
- Detection of Clone-Specific Immunoglobulin Heavy Chain Genes in the Bone Marrow of B-cell-Lineage Lymphoma after Treatment
- Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation : participation of host immune cells
- Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
- Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
- Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
- Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
- Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
- Phenotypic analysis of peripheral T/NK cell lymphoma : Study of 408 Japanese cases with special reference to their anatomical sites